Zoetis: The 60% Decline Was Justified, But Shares Are Finally Buyable

Summary

Opinion piece analyzing Zoetis's 60% stock decline and arguing the company's shares have become attractive at current valuations. No specific clinical, regulatory, or financial catalyst information is provided in the headline.